| Old | New | Differences | |
|---|---|---|---|
| 1 | - | ||
| 1 | + | CALIFORNIA LEGISLATURE 20252026 REGULAR SESSION Assembly Bill No. 602Introduced by Assembly Member Haney(Principal coauthor: Senator Wiener)February 13, 2025 An act to amend Section 1342.74 of the Health and Safety Code, and to amend Section 10123.1933 of the Insurance Code, relating to health care coverage. LEGISLATIVE COUNSEL'S DIGESTAB 602, as introduced, Haney. Health care coverage: antiretroviral drugs. Existing law, the Knox-Keene Health Care Service Plan Act of 1975, provides for the licensure and regulation of health care service plans by the Department of Managed Health Care, and makes a willful violation of the act a crime. Existing law provides for the regulation of health insurers by the Department of Insurance. Existing law requires a health care service plan or health insurer to cover preexposure prophylaxis (PrEP) and postexposure prophylaxis (PEP) furnished by a pharmacist, and prohibits a plan or insurer from subjecting antiretroviral drugs medically necessary for the prevention of AIDS/HIV to prior authorization or step therapy, except as specified. Existing law does not require a plan or insurer to cover all therapeutically equivalent versions of a drug, device, or product for the prevention of AIDS/HIV without prior authorization or step therapy.This bill would require a health care service plan contract or health insurance policy issued, amended, or renewed on or after January 1, 2026, to cover specified antiretroviral drugs for the prevention of AIDS/HIV, including PrEP and PEP, and would prohibit the imposition of any cost-sharing or utilization review requirements for those drugs. The bill would specify that, for therapeutically equivalent coverage purposes, a long-acting injectable drug is not therapeutically equivalent to a long-acting injectable drug with a different duration. Because a willful violation of these provisions by a health care service plan would be a crime, this bill would impose a state-mandated local program.The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.This bill would provide that no reimbursement is required by this act for a specified reason.Digest Key Vote: MAJORITY Appropriation: NO Fiscal Committee: YES Local Program: YES Bill TextThe people of the State of California do enact as follows:SECTION 1. Section 1342.74 of the Health and Safety Code is amended to read:1342.74. (a) (1) Notwithstanding Section 1342.71, a health care service plan shall not subject antiretroviral drugs that are medically necessary for the prevention of AIDS/HIV, including preexposure prophylaxis or postexposure prophylaxis, to prior authorization or authorization, step therapy, or any other protocol designed to delay treatment, except as provided in paragraph (2).(2) If the United States Food and Drug Administration has approved one or more therapeutic equivalents of a drug, device, or product for the prevention of AIDS/HIV, this section does not require a health care service plan to cover all of the therapeutically equivalent versions without prior authorization or step therapy, if at least one therapeutically equivalent version is covered without prior authorization or step therapy. For purposes of this section, a long-acting injectable drug is not therapeutically equivalent to a long-acting injectable drug with a different duration.(b) Notwithstanding any other law, a health care service plan shall not prohibit, or permit a delegated pharmacy benefit manager to prohibit, a pharmacy provider from dispensing preexposure prophylaxis or postexposure prophylaxis.(c) A health care service plan shall cover preexposure prophylaxis and postexposure prophylaxis that has been furnished by a pharmacist, as authorized in Sections 4052.02 and 4052.03 of the Business and Professions Code, including the pharmacists services and related testing ordered by the pharmacist. A health care service plan shall pay or reimburse, consistent with the requirements of this chapter, for the service performed by a pharmacist at an in-network pharmacy or a pharmacist at an out-of-network pharmacy if the health care service plan has an out-of-network pharmacy benefit.(d) This section does not require a health care service plan to cover preexposure prophylaxis or postexposure prophylaxis by a pharmacist at an out-of-network pharmacy, unless the health care service plan has an out-of-network pharmacy benefit.(e)This section shall not apply to Medi-Cal managed care plans contracting with the State Department of Health Care Services pursuant to Chapter 7 (commencing with Section 14000), Chapter 8 (commencing with Section 14200), or Chapter 8.75 (commencing with Section 14590) of Part 3 of Division 9 of the Welfare and Institutions Code, to the extent that the services described in this section are excluded from coverage under the contract between the Medi-Cal managed care plans and the State Department of Health Care Services.(e) A health care service plan contract issued, amended, or renewed on or after January 1, 2026, shall provide coverage for, and shall not impose any cost-sharing or utilization review requirements for, antiretroviral drugs that are either approved by the United States Food and Drug Administration or recommended by the federal Centers for Disease Control and Prevention for the prevention of AIDS/HIV, including preexposure prophylaxis or postexposure prophylaxis.SEC. 2. Section 10123.1933 of the Insurance Code is amended to read:10123.1933. (a) (1) Notwithstanding Section 10123.201, a health insurer shall not subject antiretroviral drugs that are medically necessary for the prevention of AIDS/HIV, including preexposure prophylaxis or postexposure prophylaxis, to prior authorization or authorization, step therapy, or any other protocol designed to delay treatment, except as provided in paragraph (2).(2) If the United States Food and Drug Administration has approved one or more therapeutic equivalents of a drug, device, or product for the prevention of AIDS/HIV, this section does not require a health insurer to cover all of the therapeutically equivalent versions without prior authorization or step therapy, if at least one therapeutically equivalent version is covered without prior authorization or step therapy. For purposes of this section, a long-acting injectable drug is not therapeutically equivalent to a long-acting injectable drug with a different duration.(b) Notwithstanding any other law, a health insurer shall not prohibit, or permit a contracted pharmacy benefit manager to prohibit, a pharmacist from dispensing preexposure prophylaxis or postexposure prophylaxis.(c) A health insurer shall cover preexposure prophylaxis and postexposure prophylaxis that has been furnished by a pharmacist, as authorized in Sections 4052.02 and 4052.03 of the Business and Professions Code, including the pharmacists services and related testing ordered by the pharmacist. A health insurer shall pay or reimburse, consistent with the requirements of this chapter, for the service performed by a pharmacist at an in-network pharmacy or a pharmacist at an out-of-network pharmacy if the health insurer has an out-of-network pharmacy benefit.(d) A health insurance policy issued, amended, or renewed on or after January 1, 2026, shall provide coverage for, and shall not impose any cost-sharing or utilization review requirements for, antiretroviral drugs that are either approved by the United States Food and Drug Administration or recommended by the federal Centers for Disease Control and Prevention for the prevention of AIDS/HIV, including preexposure prophylaxis or postexposure prophylaxis.SEC. 3. No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution. | |
| 2 | 2 | ||
| 3 | - | ||
| 3 | + | CALIFORNIA LEGISLATURE 20252026 REGULAR SESSION Assembly Bill No. 602Introduced by Assembly Member Haney(Principal coauthor: Senator Wiener)February 13, 2025 An act to amend Section 1342.74 of the Health and Safety Code, and to amend Section 10123.1933 of the Insurance Code, relating to health care coverage. LEGISLATIVE COUNSEL'S DIGESTAB 602, as introduced, Haney. Health care coverage: antiretroviral drugs. Existing law, the Knox-Keene Health Care Service Plan Act of 1975, provides for the licensure and regulation of health care service plans by the Department of Managed Health Care, and makes a willful violation of the act a crime. Existing law provides for the regulation of health insurers by the Department of Insurance. Existing law requires a health care service plan or health insurer to cover preexposure prophylaxis (PrEP) and postexposure prophylaxis (PEP) furnished by a pharmacist, and prohibits a plan or insurer from subjecting antiretroviral drugs medically necessary for the prevention of AIDS/HIV to prior authorization or step therapy, except as specified. Existing law does not require a plan or insurer to cover all therapeutically equivalent versions of a drug, device, or product for the prevention of AIDS/HIV without prior authorization or step therapy.This bill would require a health care service plan contract or health insurance policy issued, amended, or renewed on or after January 1, 2026, to cover specified antiretroviral drugs for the prevention of AIDS/HIV, including PrEP and PEP, and would prohibit the imposition of any cost-sharing or utilization review requirements for those drugs. The bill would specify that, for therapeutically equivalent coverage purposes, a long-acting injectable drug is not therapeutically equivalent to a long-acting injectable drug with a different duration. Because a willful violation of these provisions by a health care service plan would be a crime, this bill would impose a state-mandated local program.The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.This bill would provide that no reimbursement is required by this act for a specified reason.Digest Key Vote: MAJORITY Appropriation: NO Fiscal Committee: YES Local Program: YES | |
| 4 | 4 | ||
| 5 | - | Amended IN Assembly March 13, 2025 | |
| 6 | 5 | ||
| 7 | - | Amended IN Assembly March 13, 2025 | |
| 6 | + | ||
| 7 | + | ||
| 8 | 8 | ||
| 9 | 9 | CALIFORNIA LEGISLATURE 20252026 REGULAR SESSION | |
| 10 | 10 | ||
| 11 | 11 | Assembly Bill | |
| 12 | 12 | ||
| 13 | 13 | No. 602 | |
| 14 | 14 | ||
| 15 | 15 | Introduced by Assembly Member Haney(Principal coauthor: Senator Wiener)February 13, 2025 | |
| 16 | 16 | ||
| 17 | 17 | Introduced by Assembly Member Haney(Principal coauthor: Senator Wiener) | |
| 18 | 18 | February 13, 2025 | |
| 19 | 19 | ||
| 20 | - | An act to amend Section 1342.74 of the Health and Safety Code, and to amend Section 10123.1933 of the Insurance Code, relating to health care coverage. | |
| 20 | + | An act to amend Section 1342.74 of the Health and Safety Code, and to amend Section 10123.1933 of the Insurance Code, relating to health care coverage. | |
| 21 | 21 | ||
| 22 | 22 | LEGISLATIVE COUNSEL'S DIGEST | |
| 23 | 23 | ||
| 24 | 24 | ## LEGISLATIVE COUNSEL'S DIGEST | |
| 25 | 25 | ||
| 26 | - | AB 602, as | |
| 26 | + | AB 602, as introduced, Haney. Health care coverage: antiretroviral drugs. | |
| 27 | 27 | ||
| 28 | - | Existing law, known as the Donahoe Higher Education Act, establishes the California Community Colleges, the California State University, and the University of California as the public segments of postsecondary education in the state. Existing law requires the Regents of the University of California, the Trustees of the California State University, and the governing board of every community college district to adopt or provide for the adoption of specific rules and regulations governing student behavior and to adopt procedures by which all students are informed of the rules and regulations, with applicable penalties, as provided. Provisions of the act apply to the University of California only to the extent that the Regents of the University of California, by appropriate resolution, act to make a provision applicable.This bill would prohibit the Chancellor of the California Community Colleges, the Trustees of the California State University, the Regents of the University of California, and every administrator at any campus of those institutions from adopting or enforcing a rule that imposes disciplinary sanctions on a student solely on the basis of acts of being under the influence of, or possessing for personal use, a controlled substance, controlled substance analog, or drug paraphernalia, under certain circumstances related to a drug-related overdose that prompted the seeking of medical assistance, and would prohibit those acts from being documented in a students disciplinary file, as provided. The bill would authorize the Chancellor of the California Community Colleges, the Trustees of the California State University, the Regents of the University of California, and every administrator at any campus of those institutions to require a student who has committed one of those acts to complete an assigned activity, as specified, and would authorize them to document the act and any assigned activity imposed in a students administrative file, as provided.Existing law, the Knox-Keene Health Care Service Plan Act of 1975, provides for the licensure and regulation of health care service plans by the Department of Managed Health Care, and makes a willful violation of the act a crime. Existing law provides for the regulation of health insurers by the Department of Insurance. Existing law requires a health care service plan or health insurer to cover preexposure prophylaxis (PrEP) and postexposure prophylaxis (PEP) furnished by a pharmacist, and prohibits a plan or insurer from subjecting antiretroviral drugs medically necessary for the prevention of AIDS/HIV to prior authorization or step therapy, except as specified. Existing law does not require a plan or insurer to cover all therapeutically equivalent versions of a drug, device, or product for the prevention of AIDS/HIV without prior authorization or step therapy.This bill would require a health care service plan contract or health insurance policy issued, amended, or renewed on or after January 1, 2026, to cover specified antiretroviral drugs for the prevention of AIDS/HIV, including PrEP and PEP, and would prohibit the imposition of any cost-sharing or utilization review requirements for those drugs. The bill would specify that, for therapeutically equivalent coverage purposes, a long-acting injectable drug is not therapeutically equivalent to a long-acting injectable drug with a different duration. Because a willful violation of these provisions by a health care service plan would be a crime, this bill would impose a state-mandated local program.The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.This bill would provide that no reimbursement is required by this act for a specified reason. | |
| 29 | - | ||
| 30 | - | Existing law, known as the Donahoe Higher Education Act, establishes the California Community Colleges, the California State University, and the University of California as the public segments of postsecondary education in the state. Existing law requires the Regents of the University of California, the Trustees of the California State University, and the governing board of every community college district to adopt or provide for the adoption of specific rules and regulations governing student behavior and to adopt procedures by which all students are informed of the rules and regulations, with applicable penalties, as provided. Provisions of the act apply to the University of California only to the extent that the Regents of the University of California, by appropriate resolution, act to make a provision applicable. | |
| 31 | - | ||
| 32 | - | This bill would prohibit the Chancellor of the California Community Colleges, the Trustees of the California State University, the Regents of the University of California, and every administrator at any campus of those institutions from adopting or enforcing a rule that imposes disciplinary sanctions on a student solely on the basis of acts of being under the influence of, or possessing for personal use, a controlled substance, controlled substance analog, or drug paraphernalia, under certain circumstances related to a drug-related overdose that prompted the seeking of medical assistance, and would prohibit those acts from being documented in a students disciplinary file, as provided. The bill would authorize the Chancellor of the California Community Colleges, the Trustees of the California State University, the Regents of the University of California, and every administrator at any campus of those institutions to require a student who has committed one of those acts to complete an assigned activity, as specified, and would authorize them to document the act and any assigned activity imposed in a students administrative file, as provided. | |
| 28 | + | Existing law, the Knox-Keene Health Care Service Plan Act of 1975, provides for the licensure and regulation of health care service plans by the Department of Managed Health Care, and makes a willful violation of the act a crime. Existing law provides for the regulation of health insurers by the Department of Insurance. Existing law requires a health care service plan or health insurer to cover preexposure prophylaxis (PrEP) and postexposure prophylaxis (PEP) furnished by a pharmacist, and prohibits a plan or insurer from subjecting antiretroviral drugs medically necessary for the prevention of AIDS/HIV to prior authorization or step therapy, except as specified. Existing law does not require a plan or insurer to cover all therapeutically equivalent versions of a drug, device, or product for the prevention of AIDS/HIV without prior authorization or step therapy.This bill would require a health care service plan contract or health insurance policy issued, amended, or renewed on or after January 1, 2026, to cover specified antiretroviral drugs for the prevention of AIDS/HIV, including PrEP and PEP, and would prohibit the imposition of any cost-sharing or utilization review requirements for those drugs. The bill would specify that, for therapeutically equivalent coverage purposes, a long-acting injectable drug is not therapeutically equivalent to a long-acting injectable drug with a different duration. Because a willful violation of these provisions by a health care service plan would be a crime, this bill would impose a state-mandated local program.The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.This bill would provide that no reimbursement is required by this act for a specified reason. | |
| 33 | 29 | ||
| 34 | 30 | Existing law, the Knox-Keene Health Care Service Plan Act of 1975, provides for the licensure and regulation of health care service plans by the Department of Managed Health Care, and makes a willful violation of the act a crime. Existing law provides for the regulation of health insurers by the Department of Insurance. Existing law requires a health care service plan or health insurer to cover preexposure prophylaxis (PrEP) and postexposure prophylaxis (PEP) furnished by a pharmacist, and prohibits a plan or insurer from subjecting antiretroviral drugs medically necessary for the prevention of AIDS/HIV to prior authorization or step therapy, except as specified. Existing law does not require a plan or insurer to cover all therapeutically equivalent versions of a drug, device, or product for the prevention of AIDS/HIV without prior authorization or step therapy. | |
| 35 | 31 | ||
| 36 | - | ||
| 37 | - | ||
| 38 | 32 | This bill would require a health care service plan contract or health insurance policy issued, amended, or renewed on or after January 1, 2026, to cover specified antiretroviral drugs for the prevention of AIDS/HIV, including PrEP and PEP, and would prohibit the imposition of any cost-sharing or utilization review requirements for those drugs. The bill would specify that, for therapeutically equivalent coverage purposes, a long-acting injectable drug is not therapeutically equivalent to a long-acting injectable drug with a different duration. Because a willful violation of these provisions by a health care service plan would be a crime, this bill would impose a state-mandated local program. | |
| 39 | - | ||
| 40 | - | ||
| 41 | 33 | ||
| 42 | 34 | The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement. | |
| 43 | 35 | ||
| 44 | - | ||
| 45 | - | ||
| 46 | 36 | This bill would provide that no reimbursement is required by this act for a specified reason. | |
| 47 | - | ||
| 48 | - | ||
| 49 | 37 | ||
| 50 | 38 | ## Digest Key | |
| 51 | 39 | ||
| 52 | 40 | ## Bill Text | |
| 53 | 41 | ||
| 54 | - | The people of the State of California do enact as follows:SECTION 1. | |
| 42 | + | The people of the State of California do enact as follows:SECTION 1. Section 1342.74 of the Health and Safety Code is amended to read:1342.74. (a) (1) Notwithstanding Section 1342.71, a health care service plan shall not subject antiretroviral drugs that are medically necessary for the prevention of AIDS/HIV, including preexposure prophylaxis or postexposure prophylaxis, to prior authorization or authorization, step therapy, or any other protocol designed to delay treatment, except as provided in paragraph (2).(2) If the United States Food and Drug Administration has approved one or more therapeutic equivalents of a drug, device, or product for the prevention of AIDS/HIV, this section does not require a health care service plan to cover all of the therapeutically equivalent versions without prior authorization or step therapy, if at least one therapeutically equivalent version is covered without prior authorization or step therapy. For purposes of this section, a long-acting injectable drug is not therapeutically equivalent to a long-acting injectable drug with a different duration.(b) Notwithstanding any other law, a health care service plan shall not prohibit, or permit a delegated pharmacy benefit manager to prohibit, a pharmacy provider from dispensing preexposure prophylaxis or postexposure prophylaxis.(c) A health care service plan shall cover preexposure prophylaxis and postexposure prophylaxis that has been furnished by a pharmacist, as authorized in Sections 4052.02 and 4052.03 of the Business and Professions Code, including the pharmacists services and related testing ordered by the pharmacist. A health care service plan shall pay or reimburse, consistent with the requirements of this chapter, for the service performed by a pharmacist at an in-network pharmacy or a pharmacist at an out-of-network pharmacy if the health care service plan has an out-of-network pharmacy benefit.(d) This section does not require a health care service plan to cover preexposure prophylaxis or postexposure prophylaxis by a pharmacist at an out-of-network pharmacy, unless the health care service plan has an out-of-network pharmacy benefit.(e)This section shall not apply to Medi-Cal managed care plans contracting with the State Department of Health Care Services pursuant to Chapter 7 (commencing with Section 14000), Chapter 8 (commencing with Section 14200), or Chapter 8.75 (commencing with Section 14590) of Part 3 of Division 9 of the Welfare and Institutions Code, to the extent that the services described in this section are excluded from coverage under the contract between the Medi-Cal managed care plans and the State Department of Health Care Services.(e) A health care service plan contract issued, amended, or renewed on or after January 1, 2026, shall provide coverage for, and shall not impose any cost-sharing or utilization review requirements for, antiretroviral drugs that are either approved by the United States Food and Drug Administration or recommended by the federal Centers for Disease Control and Prevention for the prevention of AIDS/HIV, including preexposure prophylaxis or postexposure prophylaxis.SEC. 2. Section 10123.1933 of the Insurance Code is amended to read:10123.1933. (a) (1) Notwithstanding Section 10123.201, a health insurer shall not subject antiretroviral drugs that are medically necessary for the prevention of AIDS/HIV, including preexposure prophylaxis or postexposure prophylaxis, to prior authorization or authorization, step therapy, or any other protocol designed to delay treatment, except as provided in paragraph (2).(2) If the United States Food and Drug Administration has approved one or more therapeutic equivalents of a drug, device, or product for the prevention of AIDS/HIV, this section does not require a health insurer to cover all of the therapeutically equivalent versions without prior authorization or step therapy, if at least one therapeutically equivalent version is covered without prior authorization or step therapy. For purposes of this section, a long-acting injectable drug is not therapeutically equivalent to a long-acting injectable drug with a different duration.(b) Notwithstanding any other law, a health insurer shall not prohibit, or permit a contracted pharmacy benefit manager to prohibit, a pharmacist from dispensing preexposure prophylaxis or postexposure prophylaxis.(c) A health insurer shall cover preexposure prophylaxis and postexposure prophylaxis that has been furnished by a pharmacist, as authorized in Sections 4052.02 and 4052.03 of the Business and Professions Code, including the pharmacists services and related testing ordered by the pharmacist. A health insurer shall pay or reimburse, consistent with the requirements of this chapter, for the service performed by a pharmacist at an in-network pharmacy or a pharmacist at an out-of-network pharmacy if the health insurer has an out-of-network pharmacy benefit.(d) A health insurance policy issued, amended, or renewed on or after January 1, 2026, shall provide coverage for, and shall not impose any cost-sharing or utilization review requirements for, antiretroviral drugs that are either approved by the United States Food and Drug Administration or recommended by the federal Centers for Disease Control and Prevention for the prevention of AIDS/HIV, including preexposure prophylaxis or postexposure prophylaxis.SEC. 3. No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution. | |
| 55 | 43 | ||
| 56 | 44 | The people of the State of California do enact as follows: | |
| 57 | 45 | ||
| 58 | 46 | ## The people of the State of California do enact as follows: | |
| 59 | 47 | ||
| 60 | - | SECTION 1. Section | |
| 48 | + | SECTION 1. Section 1342.74 of the Health and Safety Code is amended to read:1342.74. (a) (1) Notwithstanding Section 1342.71, a health care service plan shall not subject antiretroviral drugs that are medically necessary for the prevention of AIDS/HIV, including preexposure prophylaxis or postexposure prophylaxis, to prior authorization or authorization, step therapy, or any other protocol designed to delay treatment, except as provided in paragraph (2).(2) If the United States Food and Drug Administration has approved one or more therapeutic equivalents of a drug, device, or product for the prevention of AIDS/HIV, this section does not require a health care service plan to cover all of the therapeutically equivalent versions without prior authorization or step therapy, if at least one therapeutically equivalent version is covered without prior authorization or step therapy. For purposes of this section, a long-acting injectable drug is not therapeutically equivalent to a long-acting injectable drug with a different duration.(b) Notwithstanding any other law, a health care service plan shall not prohibit, or permit a delegated pharmacy benefit manager to prohibit, a pharmacy provider from dispensing preexposure prophylaxis or postexposure prophylaxis.(c) A health care service plan shall cover preexposure prophylaxis and postexposure prophylaxis that has been furnished by a pharmacist, as authorized in Sections 4052.02 and 4052.03 of the Business and Professions Code, including the pharmacists services and related testing ordered by the pharmacist. A health care service plan shall pay or reimburse, consistent with the requirements of this chapter, for the service performed by a pharmacist at an in-network pharmacy or a pharmacist at an out-of-network pharmacy if the health care service plan has an out-of-network pharmacy benefit.(d) This section does not require a health care service plan to cover preexposure prophylaxis or postexposure prophylaxis by a pharmacist at an out-of-network pharmacy, unless the health care service plan has an out-of-network pharmacy benefit.(e)This section shall not apply to Medi-Cal managed care plans contracting with the State Department of Health Care Services pursuant to Chapter 7 (commencing with Section 14000), Chapter 8 (commencing with Section 14200), or Chapter 8.75 (commencing with Section 14590) of Part 3 of Division 9 of the Welfare and Institutions Code, to the extent that the services described in this section are excluded from coverage under the contract between the Medi-Cal managed care plans and the State Department of Health Care Services.(e) A health care service plan contract issued, amended, or renewed on or after January 1, 2026, shall provide coverage for, and shall not impose any cost-sharing or utilization review requirements for, antiretroviral drugs that are either approved by the United States Food and Drug Administration or recommended by the federal Centers for Disease Control and Prevention for the prevention of AIDS/HIV, including preexposure prophylaxis or postexposure prophylaxis. | |
| 61 | 49 | ||
| 62 | - | SECTION 1. Section | |
| 50 | + | SECTION 1. Section 1342.74 of the Health and Safety Code is amended to read: | |
| 63 | 51 | ||
| 64 | 52 | ### SECTION 1. | |
| 65 | 53 | ||
| 66 | - | ||
| 54 | + | 1342.74. (a) (1) Notwithstanding Section 1342.71, a health care service plan shall not subject antiretroviral drugs that are medically necessary for the prevention of AIDS/HIV, including preexposure prophylaxis or postexposure prophylaxis, to prior authorization or authorization, step therapy, or any other protocol designed to delay treatment, except as provided in paragraph (2).(2) If the United States Food and Drug Administration has approved one or more therapeutic equivalents of a drug, device, or product for the prevention of AIDS/HIV, this section does not require a health care service plan to cover all of the therapeutically equivalent versions without prior authorization or step therapy, if at least one therapeutically equivalent version is covered without prior authorization or step therapy. For purposes of this section, a long-acting injectable drug is not therapeutically equivalent to a long-acting injectable drug with a different duration.(b) Notwithstanding any other law, a health care service plan shall not prohibit, or permit a delegated pharmacy benefit manager to prohibit, a pharmacy provider from dispensing preexposure prophylaxis or postexposure prophylaxis.(c) A health care service plan shall cover preexposure prophylaxis and postexposure prophylaxis that has been furnished by a pharmacist, as authorized in Sections 4052.02 and 4052.03 of the Business and Professions Code, including the pharmacists services and related testing ordered by the pharmacist. A health care service plan shall pay or reimburse, consistent with the requirements of this chapter, for the service performed by a pharmacist at an in-network pharmacy or a pharmacist at an out-of-network pharmacy if the health care service plan has an out-of-network pharmacy benefit.(d) This section does not require a health care service plan to cover preexposure prophylaxis or postexposure prophylaxis by a pharmacist at an out-of-network pharmacy, unless the health care service plan has an out-of-network pharmacy benefit.(e)This section shall not apply to Medi-Cal managed care plans contracting with the State Department of Health Care Services pursuant to Chapter 7 (commencing with Section 14000), Chapter 8 (commencing with Section 14200), or Chapter 8.75 (commencing with Section 14590) of Part 3 of Division 9 of the Welfare and Institutions Code, to the extent that the services described in this section are excluded from coverage under the contract between the Medi-Cal managed care plans and the State Department of Health Care Services.(e) A health care service plan contract issued, amended, or renewed on or after January 1, 2026, shall provide coverage for, and shall not impose any cost-sharing or utilization review requirements for, antiretroviral drugs that are either approved by the United States Food and Drug Administration or recommended by the federal Centers for Disease Control and Prevention for the prevention of AIDS/HIV, including preexposure prophylaxis or postexposure prophylaxis. | |
| 67 | 55 | ||
| 68 | - | ||
| 56 | + | 1342.74. (a) (1) Notwithstanding Section 1342.71, a health care service plan shall not subject antiretroviral drugs that are medically necessary for the prevention of AIDS/HIV, including preexposure prophylaxis or postexposure prophylaxis, to prior authorization or authorization, step therapy, or any other protocol designed to delay treatment, except as provided in paragraph (2).(2) If the United States Food and Drug Administration has approved one or more therapeutic equivalents of a drug, device, or product for the prevention of AIDS/HIV, this section does not require a health care service plan to cover all of the therapeutically equivalent versions without prior authorization or step therapy, if at least one therapeutically equivalent version is covered without prior authorization or step therapy. For purposes of this section, a long-acting injectable drug is not therapeutically equivalent to a long-acting injectable drug with a different duration.(b) Notwithstanding any other law, a health care service plan shall not prohibit, or permit a delegated pharmacy benefit manager to prohibit, a pharmacy provider from dispensing preexposure prophylaxis or postexposure prophylaxis.(c) A health care service plan shall cover preexposure prophylaxis and postexposure prophylaxis that has been furnished by a pharmacist, as authorized in Sections 4052.02 and 4052.03 of the Business and Professions Code, including the pharmacists services and related testing ordered by the pharmacist. A health care service plan shall pay or reimburse, consistent with the requirements of this chapter, for the service performed by a pharmacist at an in-network pharmacy or a pharmacist at an out-of-network pharmacy if the health care service plan has an out-of-network pharmacy benefit.(d) This section does not require a health care service plan to cover preexposure prophylaxis or postexposure prophylaxis by a pharmacist at an out-of-network pharmacy, unless the health care service plan has an out-of-network pharmacy benefit.(e)This section shall not apply to Medi-Cal managed care plans contracting with the State Department of Health Care Services pursuant to Chapter 7 (commencing with Section 14000), Chapter 8 (commencing with Section 14200), or Chapter 8.75 (commencing with Section 14590) of Part 3 of Division 9 of the Welfare and Institutions Code, to the extent that the services described in this section are excluded from coverage under the contract between the Medi-Cal managed care plans and the State Department of Health Care Services.(e) A health care service plan contract issued, amended, or renewed on or after January 1, 2026, shall provide coverage for, and shall not impose any cost-sharing or utilization review requirements for, antiretroviral drugs that are either approved by the United States Food and Drug Administration or recommended by the federal Centers for Disease Control and Prevention for the prevention of AIDS/HIV, including preexposure prophylaxis or postexposure prophylaxis. | |
| 69 | 57 | ||
| 70 | - | ||
| 58 | + | 1342.74. (a) (1) Notwithstanding Section 1342.71, a health care service plan shall not subject antiretroviral drugs that are medically necessary for the prevention of AIDS/HIV, including preexposure prophylaxis or postexposure prophylaxis, to prior authorization or authorization, step therapy, or any other protocol designed to delay treatment, except as provided in paragraph (2).(2) If the United States Food and Drug Administration has approved one or more therapeutic equivalents of a drug, device, or product for the prevention of AIDS/HIV, this section does not require a health care service plan to cover all of the therapeutically equivalent versions without prior authorization or step therapy, if at least one therapeutically equivalent version is covered without prior authorization or step therapy. For purposes of this section, a long-acting injectable drug is not therapeutically equivalent to a long-acting injectable drug with a different duration.(b) Notwithstanding any other law, a health care service plan shall not prohibit, or permit a delegated pharmacy benefit manager to prohibit, a pharmacy provider from dispensing preexposure prophylaxis or postexposure prophylaxis.(c) A health care service plan shall cover preexposure prophylaxis and postexposure prophylaxis that has been furnished by a pharmacist, as authorized in Sections 4052.02 and 4052.03 of the Business and Professions Code, including the pharmacists services and related testing ordered by the pharmacist. A health care service plan shall pay or reimburse, consistent with the requirements of this chapter, for the service performed by a pharmacist at an in-network pharmacy or a pharmacist at an out-of-network pharmacy if the health care service plan has an out-of-network pharmacy benefit.(d) This section does not require a health care service plan to cover preexposure prophylaxis or postexposure prophylaxis by a pharmacist at an out-of-network pharmacy, unless the health care service plan has an out-of-network pharmacy benefit.(e)This section shall not apply to Medi-Cal managed care plans contracting with the State Department of Health Care Services pursuant to Chapter 7 (commencing with Section 14000), Chapter 8 (commencing with Section 14200), or Chapter 8.75 (commencing with Section 14590) of Part 3 of Division 9 of the Welfare and Institutions Code, to the extent that the services described in this section are excluded from coverage under the contract between the Medi-Cal managed care plans and the State Department of Health Care Services.(e) A health care service plan contract issued, amended, or renewed on or after January 1, 2026, shall provide coverage for, and shall not impose any cost-sharing or utilization review requirements for, antiretroviral drugs that are either approved by the United States Food and Drug Administration or recommended by the federal Centers for Disease Control and Prevention for the prevention of AIDS/HIV, including preexposure prophylaxis or postexposure prophylaxis. | |
| 71 | 59 | ||
| 72 | 60 | ||
| 73 | 61 | ||
| 74 | - | 66301.5. (a) The Chancellor of the California Community Colleges, the Trustees of the California State University, the Regents of the University of California, and every administrator at any campus of those institutions shall not adopt or enforce a rule that imposes disciplinary sanctions on a student solely on the basis of either of the following acts: | |
| 75 | - | ||
| 76 | - | (1) Being under the influence of, or possessing for personal use, a controlled substance, controlled substance analog, or drug paraphernalia, if the student, in good faith, seeks medical assistance for a person experiencing a drug-related overdose that is related to the possession of a controlled substance, controlled substance analog, or drug paraphernalia of the student seeking medical assistance, and the student does not obstruct medical or law enforcement personnel. | |
| 77 | - | ||
| 78 | - | (2) Experiencing a drug-related overdose and being in need of medical assistance while being under the influence of, or possessing for personal use, a controlled substance, controlled substance analog, or drug paraphernalia, if the student or one or more other persons at the scene of the overdose, in good faith, seeks medical assistance for the student experiencing the overdose. | |
| 79 | - | ||
| 80 | - | (b) (1) The Chancellor of the California Community Colleges, the Trustees of the California State University, the Regents of the University of California, and every administrator at any campus of those institutions may require a student who has committed an act specified in subdivision (a) to complete an assigned activity, such as participating in meetings with a school counselor or attending a drug education group, but shall not otherwise sanction the student. | |
| 81 | - | ||
| 82 | - | (2) The Chancellor of the California Community Colleges, the Trustees of the California State University, the Regents of the University of California, and the administrators at each campus of those institutions may document an act specified in subdivision (a) and any requirements imposed pursuant to paragraph (1) in a students administrative file, but shall not document the act or any related requirement in a disciplinary file. | |
| 83 | - | ||
| 84 | - | ||
| 85 | - | ||
| 86 | - | ||
| 87 | - | ||
| 88 | - | (a)(1)Notwithstanding Section 1342.71, a health care service plan shall not subject antiretroviral drugs that are medically necessary for the prevention of AIDS/HIV, including preexposure prophylaxis or postexposure prophylaxis, to prior authorization, step therapy, or any other protocol designed to delay treatment, except as provided in paragraph (2). | |
| 89 | - | ||
| 90 | - | ||
| 62 | + | 1342.74. (a) (1) Notwithstanding Section 1342.71, a health care service plan shall not subject antiretroviral drugs that are medically necessary for the prevention of AIDS/HIV, including preexposure prophylaxis or postexposure prophylaxis, to prior authorization or authorization, step therapy, or any other protocol designed to delay treatment, except as provided in paragraph (2). | |
| 91 | 63 | ||
| 92 | 64 | (2) If the United States Food and Drug Administration has approved one or more therapeutic equivalents of a drug, device, or product for the prevention of AIDS/HIV, this section does not require a health care service plan to cover all of the therapeutically equivalent versions without prior authorization or step therapy, if at least one therapeutically equivalent version is covered without prior authorization or step therapy. For purposes of this section, a long-acting injectable drug is not therapeutically equivalent to a long-acting injectable drug with a different duration. | |
| 93 | 65 | ||
| 94 | - | ||
| 95 | - | ||
| 96 | 66 | (b) Notwithstanding any other law, a health care service plan shall not prohibit, or permit a delegated pharmacy benefit manager to prohibit, a pharmacy provider from dispensing preexposure prophylaxis or postexposure prophylaxis. | |
| 97 | - | ||
| 98 | - | ||
| 99 | 67 | ||
| 100 | 68 | (c) A health care service plan shall cover preexposure prophylaxis and postexposure prophylaxis that has been furnished by a pharmacist, as authorized in Sections 4052.02 and 4052.03 of the Business and Professions Code, including the pharmacists services and related testing ordered by the pharmacist. A health care service plan shall pay or reimburse, consistent with the requirements of this chapter, for the service performed by a pharmacist at an in-network pharmacy or a pharmacist at an out-of-network pharmacy if the health care service plan has an out-of-network pharmacy benefit. | |
| 101 | 69 | ||
| 70 | + | (d) This section does not require a health care service plan to cover preexposure prophylaxis or postexposure prophylaxis by a pharmacist at an out-of-network pharmacy, unless the health care service plan has an out-of-network pharmacy benefit. | |
| 102 | 71 | ||
| 103 | - | ||
| 104 | - | (d)This section does not require a health care service plan to cover preexposure prophylaxis or postexposure prophylaxis by a pharmacist at an out-of-network pharmacy, unless the health care service plan has an out-of-network pharmacy benefit. | |
| 72 | + | (e)This section shall not apply to Medi-Cal managed care plans contracting with the State Department of Health Care Services pursuant to Chapter 7 (commencing with Section 14000), Chapter 8 (commencing with Section 14200), or Chapter 8.75 (commencing with Section 14590) of Part 3 of Division 9 of the Welfare and Institutions Code, to the extent that the services described in this section are excluded from coverage under the contract between the Medi-Cal managed care plans and the State Department of Health Care Services. | |
| 105 | 73 | ||
| 106 | 74 | ||
| 107 | 75 | ||
| 108 | 76 | (e) A health care service plan contract issued, amended, or renewed on or after January 1, 2026, shall provide coverage for, and shall not impose any cost-sharing or utilization review requirements for, antiretroviral drugs that are either approved by the United States Food and Drug Administration or recommended by the federal Centers for Disease Control and Prevention for the prevention of AIDS/HIV, including preexposure prophylaxis or postexposure prophylaxis. | |
| 109 | 77 | ||
| 78 | + | SEC. 2. Section 10123.1933 of the Insurance Code is amended to read:10123.1933. (a) (1) Notwithstanding Section 10123.201, a health insurer shall not subject antiretroviral drugs that are medically necessary for the prevention of AIDS/HIV, including preexposure prophylaxis or postexposure prophylaxis, to prior authorization or authorization, step therapy, or any other protocol designed to delay treatment, except as provided in paragraph (2).(2) If the United States Food and Drug Administration has approved one or more therapeutic equivalents of a drug, device, or product for the prevention of AIDS/HIV, this section does not require a health insurer to cover all of the therapeutically equivalent versions without prior authorization or step therapy, if at least one therapeutically equivalent version is covered without prior authorization or step therapy. For purposes of this section, a long-acting injectable drug is not therapeutically equivalent to a long-acting injectable drug with a different duration.(b) Notwithstanding any other law, a health insurer shall not prohibit, or permit a contracted pharmacy benefit manager to prohibit, a pharmacist from dispensing preexposure prophylaxis or postexposure prophylaxis.(c) A health insurer shall cover preexposure prophylaxis and postexposure prophylaxis that has been furnished by a pharmacist, as authorized in Sections 4052.02 and 4052.03 of the Business and Professions Code, including the pharmacists services and related testing ordered by the pharmacist. A health insurer shall pay or reimburse, consistent with the requirements of this chapter, for the service performed by a pharmacist at an in-network pharmacy or a pharmacist at an out-of-network pharmacy if the health insurer has an out-of-network pharmacy benefit.(d) A health insurance policy issued, amended, or renewed on or after January 1, 2026, shall provide coverage for, and shall not impose any cost-sharing or utilization review requirements for, antiretroviral drugs that are either approved by the United States Food and Drug Administration or recommended by the federal Centers for Disease Control and Prevention for the prevention of AIDS/HIV, including preexposure prophylaxis or postexposure prophylaxis. | |
| 79 | + | ||
| 80 | + | SEC. 2. Section 10123.1933 of the Insurance Code is amended to read: | |
| 81 | + | ||
| 82 | + | ### SEC. 2. | |
| 83 | + | ||
| 84 | + | 10123.1933. (a) (1) Notwithstanding Section 10123.201, a health insurer shall not subject antiretroviral drugs that are medically necessary for the prevention of AIDS/HIV, including preexposure prophylaxis or postexposure prophylaxis, to prior authorization or authorization, step therapy, or any other protocol designed to delay treatment, except as provided in paragraph (2).(2) If the United States Food and Drug Administration has approved one or more therapeutic equivalents of a drug, device, or product for the prevention of AIDS/HIV, this section does not require a health insurer to cover all of the therapeutically equivalent versions without prior authorization or step therapy, if at least one therapeutically equivalent version is covered without prior authorization or step therapy. For purposes of this section, a long-acting injectable drug is not therapeutically equivalent to a long-acting injectable drug with a different duration.(b) Notwithstanding any other law, a health insurer shall not prohibit, or permit a contracted pharmacy benefit manager to prohibit, a pharmacist from dispensing preexposure prophylaxis or postexposure prophylaxis.(c) A health insurer shall cover preexposure prophylaxis and postexposure prophylaxis that has been furnished by a pharmacist, as authorized in Sections 4052.02 and 4052.03 of the Business and Professions Code, including the pharmacists services and related testing ordered by the pharmacist. A health insurer shall pay or reimburse, consistent with the requirements of this chapter, for the service performed by a pharmacist at an in-network pharmacy or a pharmacist at an out-of-network pharmacy if the health insurer has an out-of-network pharmacy benefit.(d) A health insurance policy issued, amended, or renewed on or after January 1, 2026, shall provide coverage for, and shall not impose any cost-sharing or utilization review requirements for, antiretroviral drugs that are either approved by the United States Food and Drug Administration or recommended by the federal Centers for Disease Control and Prevention for the prevention of AIDS/HIV, including preexposure prophylaxis or postexposure prophylaxis. | |
| 85 | + | ||
| 86 | + | 10123.1933. (a) (1) Notwithstanding Section 10123.201, a health insurer shall not subject antiretroviral drugs that are medically necessary for the prevention of AIDS/HIV, including preexposure prophylaxis or postexposure prophylaxis, to prior authorization or authorization, step therapy, or any other protocol designed to delay treatment, except as provided in paragraph (2).(2) If the United States Food and Drug Administration has approved one or more therapeutic equivalents of a drug, device, or product for the prevention of AIDS/HIV, this section does not require a health insurer to cover all of the therapeutically equivalent versions without prior authorization or step therapy, if at least one therapeutically equivalent version is covered without prior authorization or step therapy. For purposes of this section, a long-acting injectable drug is not therapeutically equivalent to a long-acting injectable drug with a different duration.(b) Notwithstanding any other law, a health insurer shall not prohibit, or permit a contracted pharmacy benefit manager to prohibit, a pharmacist from dispensing preexposure prophylaxis or postexposure prophylaxis.(c) A health insurer shall cover preexposure prophylaxis and postexposure prophylaxis that has been furnished by a pharmacist, as authorized in Sections 4052.02 and 4052.03 of the Business and Professions Code, including the pharmacists services and related testing ordered by the pharmacist. A health insurer shall pay or reimburse, consistent with the requirements of this chapter, for the service performed by a pharmacist at an in-network pharmacy or a pharmacist at an out-of-network pharmacy if the health insurer has an out-of-network pharmacy benefit.(d) A health insurance policy issued, amended, or renewed on or after January 1, 2026, shall provide coverage for, and shall not impose any cost-sharing or utilization review requirements for, antiretroviral drugs that are either approved by the United States Food and Drug Administration or recommended by the federal Centers for Disease Control and Prevention for the prevention of AIDS/HIV, including preexposure prophylaxis or postexposure prophylaxis. | |
| 87 | + | ||
| 88 | + | 10123.1933. (a) (1) Notwithstanding Section 10123.201, a health insurer shall not subject antiretroviral drugs that are medically necessary for the prevention of AIDS/HIV, including preexposure prophylaxis or postexposure prophylaxis, to prior authorization or authorization, step therapy, or any other protocol designed to delay treatment, except as provided in paragraph (2).(2) If the United States Food and Drug Administration has approved one or more therapeutic equivalents of a drug, device, or product for the prevention of AIDS/HIV, this section does not require a health insurer to cover all of the therapeutically equivalent versions without prior authorization or step therapy, if at least one therapeutically equivalent version is covered without prior authorization or step therapy. For purposes of this section, a long-acting injectable drug is not therapeutically equivalent to a long-acting injectable drug with a different duration.(b) Notwithstanding any other law, a health insurer shall not prohibit, or permit a contracted pharmacy benefit manager to prohibit, a pharmacist from dispensing preexposure prophylaxis or postexposure prophylaxis.(c) A health insurer shall cover preexposure prophylaxis and postexposure prophylaxis that has been furnished by a pharmacist, as authorized in Sections 4052.02 and 4052.03 of the Business and Professions Code, including the pharmacists services and related testing ordered by the pharmacist. A health insurer shall pay or reimburse, consistent with the requirements of this chapter, for the service performed by a pharmacist at an in-network pharmacy or a pharmacist at an out-of-network pharmacy if the health insurer has an out-of-network pharmacy benefit.(d) A health insurance policy issued, amended, or renewed on or after January 1, 2026, shall provide coverage for, and shall not impose any cost-sharing or utilization review requirements for, antiretroviral drugs that are either approved by the United States Food and Drug Administration or recommended by the federal Centers for Disease Control and Prevention for the prevention of AIDS/HIV, including preexposure prophylaxis or postexposure prophylaxis. | |
| 110 | 89 | ||
| 111 | 90 | ||
| 112 | 91 | ||
| 113 | - | ||
| 114 | - | ||
| 115 | - | ||
| 116 | - | (a)(1)Notwithstanding Section 10123.201, a health insurer shall not subject antiretroviral drugs that are medically necessary for the prevention of AIDS/HIV, including preexposure prophylaxis or postexposure prophylaxis, to prior authorization, step therapy, or any other protocol designed to delay treatment, except as provided in paragraph (2). | |
| 117 | - | ||
| 118 | - | ||
| 92 | + | 10123.1933. (a) (1) Notwithstanding Section 10123.201, a health insurer shall not subject antiretroviral drugs that are medically necessary for the prevention of AIDS/HIV, including preexposure prophylaxis or postexposure prophylaxis, to prior authorization or authorization, step therapy, or any other protocol designed to delay treatment, except as provided in paragraph (2). | |
| 119 | 93 | ||
| 120 | 94 | (2) If the United States Food and Drug Administration has approved one or more therapeutic equivalents of a drug, device, or product for the prevention of AIDS/HIV, this section does not require a health insurer to cover all of the therapeutically equivalent versions without prior authorization or step therapy, if at least one therapeutically equivalent version is covered without prior authorization or step therapy. For purposes of this section, a long-acting injectable drug is not therapeutically equivalent to a long-acting injectable drug with a different duration. | |
| 121 | 95 | ||
| 122 | - | ||
| 123 | - | ||
| 124 | 96 | (b) Notwithstanding any other law, a health insurer shall not prohibit, or permit a contracted pharmacy benefit manager to prohibit, a pharmacist from dispensing preexposure prophylaxis or postexposure prophylaxis. | |
| 125 | - | ||
| 126 | - | ||
| 127 | 97 | ||
| 128 | 98 | (c) A health insurer shall cover preexposure prophylaxis and postexposure prophylaxis that has been furnished by a pharmacist, as authorized in Sections 4052.02 and 4052.03 of the Business and Professions Code, including the pharmacists services and related testing ordered by the pharmacist. A health insurer shall pay or reimburse, consistent with the requirements of this chapter, for the service performed by a pharmacist at an in-network pharmacy or a pharmacist at an out-of-network pharmacy if the health insurer has an out-of-network pharmacy benefit. | |
| 129 | 99 | ||
| 130 | - | ||
| 131 | - | ||
| 132 | 100 | (d) A health insurance policy issued, amended, or renewed on or after January 1, 2026, shall provide coverage for, and shall not impose any cost-sharing or utilization review requirements for, antiretroviral drugs that are either approved by the United States Food and Drug Administration or recommended by the federal Centers for Disease Control and Prevention for the prevention of AIDS/HIV, including preexposure prophylaxis or postexposure prophylaxis. | |
| 133 | 101 | ||
| 102 | + | SEC. 3. No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution. | |
| 134 | 103 | ||
| 104 | + | SEC. 3. No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution. | |
| 135 | 105 | ||
| 106 | + | SEC. 3. No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution. | |
| 136 | 107 | ||
| 137 | - | ||
| 138 | - | No reimbursement is required by this act pursuant to Section 6 of Article XIII B of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIII B of the California Constitution. | |
| 108 | + | ### SEC. 3. |